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The integrity of our organs and tissues is
maintained by a complex network of
genes that regulate cellular proliferation,
differentiation, and death. Cancers arise
when mutations in key genes cause this
network to fail. Based on the age-depen-
dent kinetics of cancer incidence, it has
been estimated that human cancers
require 4–6 cooperating mutations to
achieve the fully malignant phenotype
(Hahn and Weinberg, 2002). Cancer
geneticists have developed a variety of
clever strategies to identify and catalog
the genes responsible for each type of
cancer. A number of extraordinarily inter-
esting genes have been discovered, and it
is largely through the study of these
genes that our current understanding of
the cancer process has emerged.
Although a few mutational targets cut
across many cancer types (e.g., p53 and
Ras), the catalog of target genes remains
incomplete. The urgency of completing
this process has been underscored by the
development of drugs that target specific
oncogenes, notably imatinib (formerly
STI-571), a breakthrough drug that tar-
gets Bcr-Abl in chronic myelogenous
leukemia and KIT in gastrointestinal stro-
mal tumors.
Although current disease-specific
strategies for identifying cancer genes are
far from exhausted, the availability of the
human genome sequence has created an
opportunity that has been seized by
Stratton and colleagues at the Sanger
Institute. Taking advantage of the
sequence and their expertise in high-
throughput genomic technologies, these
investigators are systematically combing
the genome for genes that are mutated in
human cancer. Knowing the importance
of signal transduction in cellular growth
regulation, the search has been initiated
with genes in these pathways.The logic of
this scheme was confirmed by the discov-
ery of activating mutations in BRAF
(Davies et al., 2002). Members of the Raf
family (RAF1, ARAF1, and BRAF)
encode serine/threonine kinases that act
in the MAPK pathway to transduce regu-
latory signals from Ras to MEK1/2 (Figure
1). Davies et al. have identified activating
mutations of BRAF with moderate to low
frequency in a variety of cancers including
colon (18% of cell lines and 12% of
tumors) and ovarian (4% of cell lines and
14% of tumors) carcinomas. These num-
bers pale beside the stunningly high inci-
dence of 59% in melanoma cell lines.
Importantly, this high frequency is not the
result of long-term cell culture, as the
mutation frequencies in short-term cul-
tures and melanoma tumors were also
high. In an appealing parallel to activating
mutations in Ras, which occur at charac-
teristic sites, BRAF mutations are not
scattered at random through the protein
but cluster in specific regions of the B-raf
protein. Remarkably, the preponderant
mutation (80%) is a single phospho-
mimetic substitution in the kinase activa-
tion domain (V599E), leading to constitu-
tive kinase activity (Davies et al., 2002).
It is difficult to overemphasize the
importance of the observation of BRAF
mutations to melanoma research. With
the exception of lung cancer in women,
the incidence of cutaneous malignant
melanoma (CMM) has increased more
than any other cancer in the United
States. In 2002 it is estimated that there
will be 53,600 new cases of melanoma
and 7,400 deaths. If caught early,
melanomas can be cured by surgical
removal. However, melanoma that has
metastasized to distant sites has a dismal
5-year survival of only 6%, and there is lit-
tle on the developmental therapeutics
horizon that offers much hope for these
patients. Epidemiologic evidence, sup-
ported by recent mouse models, indicates
a role for UV light exposure as a risk factor
for melanoma development, and efforts at
prevention are directed at educating the
public about the risks of sun exposure
(Noonan et al., 2001).
Prior to the discovery of BRAF muta-
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Figure 1. Melanocyte signal transduction
B-raf functions downstream of Ras in the MAPK cascade. Signals from extracellular growth reg-
ulatory factors (pink) transduced through receptor tyrosine kinases (blue) or G protein-coupled
receptors (yellow) result in activation of the MAPK pathway. The mechanisms coupling GPCR
signals to the MAPK pathway have not been fully elucidated in melanocytes but are known to
involve B-raf in other cell types. The authors thank Darryl Leja for assistance with the illustration.
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tions, somatic inactivation of the tumor
suppressor gene, CDKN2A, was the most
frequent genetic event reported in
melanoma tumors. CDKN2A encodes two
proteins, the cell cycle inhibitor p16, a
molecule that inhibits the activity of the
cyclinD/CDK4 (CDK6) kinase complex,
and p14ARF, an antagonist of the p53 regu-
lator MDM2. It is inactivated by mutation,
homozygous deletion, or methylation in
?25% of sporadic melanomas (Pollock et
al., 2001). Further evidence of the impor-
tance of this cell cycle pathway comes
from the observation of germline muta-
tions in CDKN2A in ?20% of melanoma
families worldwide and additional rare
melanoma families with germline muta-
tions in the p16 target CDK4. Less fre-
quent somatic mutations have been
reported in other well-known oncogenes
and tumor suppressor genes: NRAS
(?15%) and PTEN (?10%) (Herlyn and
Satyamoorthy, 1996; Ali et al., 1999).
Remarkably, in the Davies et al. study,
NRAS mutations did not occur in the
same melanoma cell lines that contained
BRAF mutations. This observation (which
was largely true of other cancers as well)
suggests that activation of either one of
these genes is sufficient to provide an
oncogenic stimulus in melanocytes.
Although confirmation of the BRAF
mutation frequency in a larger panel of
uncultured tumors from different stages
of disease will be an important follow-up
study, the available data lead to the
speculation that an activating mutation in
the Ras/Raf/MAPK pathway is an essen-
tial step in melanoma progression. The
high frequency of B-raf activation may
also help to explain a perplexing issue in
melanoma biology, the stark contrast
between the importance of activated Ras
to tumor initiation and maintenance in
melanoma mouse models and the low fre-
quency of activated Ras reported in
human tumors (Chin et al., 1999). This
question will surely be addressed further
by the development of an activated B-Raf
mouse model. If this exhibits a similar
phenotype to the Ras model, it would pro-
vide genetic confirmation of the impor-
tance of the MAPK pathway relative to
other possible Ras effectors to melanoma
tumorigenesis.
How does BRAF fit into melanocyte
biology? In the skin, melanocyte home-
ostasis is controlled by the regulated pro-
duction of mitogenic growth factors by
keratinocytes (e.g., bFGF, endothelin, and
MSH) and fibroblasts (e.g., bFGF, SCF,
and HGF). During transformation to mela-
noma, autocrine production of growth fac-
tors probably contributes to autonomous
tumor growth.The role of Raf is not limited
to transducing RTK mitogenic signals
through Ras but also includes mediation
of growth factor stimulation through
GPCRs (via cAMP/PKA and IP3/
DAG/PKC). In melanocytes, B-Raf has
been shown to mediate the MSH (cAMP)
activation of the MAPK pathway (Busca et
al., 2000). Endothelin-1, a strong melan-
ocyte mitogen, is another candidate for
signaling though B-raf. Et-1 can activate
the MAPK pathway, although the role of
B-raf in transducing this signal has 
not been demonstrated in melanocytes
(Imokawa et al., 1996). Data from cultured
human melanocytes demonstrates that
synergistic growth factor stimulation 
of both RTKs and GPCRs is key to
melanocyte proliferation. This synergy
suggests the importance of the crosstalk
between the AC/cAMP/PKA, the IP3/
DAG/PKC, and the Ras/Raf/MAPK path-
ways in melanocytes. Possibly, mutational
activation of B-Raf mimics the synergistic
stimulation of multiple growth factors.
When considering possible causes of
BRAF mutations in melanoma, it is impor-
tant to bear in mind the constraints
imposed by the gene sequence and the
specific oncogenic amino acid substitu-
tions that might be selected during tumor
evolution. Nonetheless, it is remarkable
that the most frequent mutation (T1796A)
is not a common UV-induced base
change; indeed, it is a relatively uncom-
mon base change in carcinogenesis
(Greenblatt et al., 1994). Both in vitro UV
mutagenesis studies in endogenous
mammalian genes and in vivo mutagene-
sis studies of the TP53 gene in squamous
cell carcinomas (SCCs) and p16 in
melanomas have shown that C→T transi-
tions at dipyrimidine sites are the most
common nucleotide change (Greenblatt
et al., 1994; Pollock et al., 1996).The next
most common changes are CC→TT and
C→A mutations. Although the common
UV-associated tandem mutation was not
observed by Davies et al., a TG→AT tan-
dem mutation was found in a melanoma
cell line. Does this mean that the V599E is
caused by a low-frequency but highly
selected UV mutation, or could the known
effect of UV on melanoma risk be mediat-
ed by mutation of another, as yet undis-
covered gene?
One of the aims remaining in mela-
noma genetics is to identify the temporal
sequence of genetic events required for
melanoma pathogenesis. Most important
is the identification of which mutational
events initiate tumor growth in the easily
curable radial growth phase, and which
are the crucial events that govern the tran-
sition from this stage to the vertically
growing invasive tumor with lethal
metastatic potential. Follow-up studies
should therefore address when, during
melanoma pathogenesis, activation of 
B-raf occurs. Mutations in N-Ras have
been reported in congenital melanocytic
nevi and early radial growth phase
melanoma, suggesting that B-raf might
also be mutated in these early lesions
(Demunter et al., 2001). Given that decou-
pling growth from extracellular signals is
one of the earlier events in melanoma
tumor formation, one might speculate that
mutation of B-raf could be an early event.
Interestingly, 4/5 ovarian cancers with
BRAF mutations identified by Davies et al.
were low-grade tumors, suggesting that at
least in some tissues, BRAF mutation
alone is insufficient to produce aggressive
tumor growth.
Enzymes are attractive targets for
small-molecule drug development, and
the question arises as to whether B-raf is
the ideal therapeutic target for melanoma.
Hopes are raised by the prevalence of
BRAF mutations in melanoma and bol-
stered somewhat by the demonstration
that the ERK1/2 inhibitor U0126 causes
decreased proliferation of melanoma cell
lines bearing BRAF mutations. However, it
also remains possible that other events in
advanced melanomas might allow these
tumors to become B-raf independent so
that targeting B-raf would not provide ade-
quate blockade of the mitogenic signal.
Uncovering BRAF mutations is an
important step forward in melanoma
research, but it is also an important indi-
cator of the potential of high-throughput
genomic approaches to cancer gene dis-
covery. How many mutations are required
for cancer to develop? Perhaps over the
next several years, we will obtain a pre-
cise enumeration.
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Medulloblastoma, a primitive neuroecto-
dermal tumor of the posterior fossa, is
the most common central nervous sys-
tem (CNS) malignancy of childhood.
Despite aggressive multimodal therapy
with surgery, radiation, and chemothera-
py, 5-year survival rates have only
recently approached >60% (Packer et
al., 1999). In this preview we will address
the genetic underpinnings of medul-
loblastoma and the role that Sonic
hedgehog (Shh) signaling plays in this
disease. Recent work by Taylor et al.
(2002) extends our understanding of
medulloblastoma oncogenesis and its
relationship to normal developmental
programs.
Medulloblastomas are thought to
derive from immature granule cells of the
cerebellum and comprise several histo-
logical and prognostic subgroups. The
desmoplastic subtype is distinguished
from “classic” medulloblastoma by the
presence of relatively acellular nodules
within the otherwise densely cellular sea
of malignant cells. Expression of particu-
lar markers, such as TrkC, in tumor cells,
has been shown to predict a relatively
favorable outcome (Louis et al., 2002). A
significant advance in our understanding
of medulloblastoma tumorigenesis was
the recognition that mutations of the Shh
receptor, Patched (PTCH), were strongly
associated with desmoplastic medul-
loblastoma. Germline PTCH mutations
are etiologic in Gorlin’s syndrome (also
called Nevoid Basal Cell Carcinoma
Syndrome), which is characterized by
developmental anomalies and high rates
of both basal cell carcinoma and medul-
loblastoma. Moreover, about 10%–20% of
sporadic tumors, typically the desmoplas-
tic variant, contain mutations within the
Shh-PTCH pathway (Louis et al., 2002).
Shh signaling is essential for the
development of the mammalian CNS and
is the major mitogenic pathway regulating
proliferation of immature granule cells of
the cerebellum (Wechsler-Reya and
Scott, 2001). hedgehog was originally
identified as a “segment polarity” gene by
Figure 1. Mutations in Hedge-
hog (Hh) signaling predispose
to tumorigenesis
Mutant alleles of PTCH and
SMOH that result in activation
of Hedgehog signaling are
etiologic in basal cell carci-
noma and medulloblastoma.
Whether SMOH signaling di-
rectly regulates GLI activity is
unclear. Recent work impli-
cates SUFU as a functional
repressor of GLI proteins that
are thought to mediate acti-
vation of Hh transcriptional
targets (Taylor et al., 2002).
SUFU proteins in the nucleus
repress GLI transcriptional ac-
tivity by recruiting SAP18, a
component of the mSin3 and
histone deacetylase com-
plex (Cheng and Bishop,
2002). Furthermore, SUFU ex-
ports GLI from the nucleus
and the cytoplasm, where is
targeted for degradation.
Together, mutations in PTCH, SMOH, and SUFU (indicated by asterisks) account for the major-
ity of cases of human desmoplastic medulloblastoma. Note that the cartoon represents a
simplified scheme for vertebrate Hh signaling with particular emphasis on oncogenic muta-
tions. For detailed summary of invertebrate Hh signaling, see Ingham and McMahon (2001).
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Medulloblastoma: A problem of developmental biology
The identification of SUFU mutations in desmoplastic medulloblastoma provides new insights into vertebrate Hedgehog
signaling and brain tumor formation.
